GLP-1s Spur Greater Reduction in Colorectal Cancer Risk than Aspirin

In a large retrospective study, those taking a glucagon-like peptide 1 (GLP-1) receptor agonist drug were 36% less likely to develop colorectal cancer than those taking aspirin. Although the benefit seen for any one person was small, thousands could potentially see a benefit given the large number of people taking GLP-1s.d.

Publication Details

Journal
Cancer Discovery
Published
2026-01-14
DOI
https://doi.org/10.1158/2159-8290.cd-nw2026-0002
Primary Topic
Diabetes Treatment and Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

GLP-1s Spur Greater Reduction in Colorectal Cancer Risk than Aspirin

Cancer Discovery
Diabetes Treatment and Management
article

GLP-1s Spur Greater Reduction in Colorectal Cancer Risk than Aspirin

article en

Abstract

In a large retrospective study, those taking a glucagon-like peptide 1 (GLP-1) receptor agonist drug were 36% less likely to develop colorectal cancer than those taking aspirin. Although the benefit seen for any one person was small, thousands could potentially see a benefit given the large number of people taking GLP-1s.d.

Cancer DiscoveryVol. 16(3)
Good health and well-being
Openalex Percentile: Top 87%
Diabetes Treatment and Management
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

GLP-1s Spur Greater Reduction in Colorectal Cancer Risk than Aspirin · Cancer Discovery (2026) | TGRS Research Map | TGRS